Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: Minocycline

David C Hess, Susan C. Fagan

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

There is only 1 US Food and Drug Administration-approved drug for acute ischemic stroke: tissue plasminogen activator (tPA). Due to a short time window and fear of intracerebral hemorrhage (ICH), tPA remains underutilized. There is great interest in developing combination drugs to use with tPA to improve the odds of a favorable recovery and to reduce the risk of ICH. Minocycline is a broad-spectrum antibiotic that has been found to be a neuroprotective agent in preclinical ischemic stroke models. Minocycline inhibits matrix metalloproteinase-9, a biomarker for ICH associated with tPA use. Minocycline is also an anti-inflammatory agent and inhibits poly (ADP-ribose) polymerase-1. Minocycline has been safe and well tolerated in the clinical trials conducted to date.

Original languageEnglish (US)
JournalReviews in Neurological Diseases
Volume7
Issue numberSUPPL. 1
DOIs
StatePublished - Aug 20 2010

Keywords

  • Acute ischemic stroke
  • Minocycline
  • MMP-9
  • PARP-1
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: Minocycline'. Together they form a unique fingerprint.

  • Cite this